Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOTRIMIN vs EXELDERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis,Vaginal treatment of vulvovaginal candidiasis
Tinea pedis,Tinea cruris,Tinea corporis,Tinea versicolor
Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.
Apply a thin layer to affected skin twice daily (morning and evening).
Terminal elimination half-life is approximately 20-50 hours. Dose adjustments not required in renal impairment, but caution in hepatic impairment.
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Hepatic metabolism via CYP3A4 and CYP2C9; excreted in feces and urine as metabolites.
Minimal systemic absorption; when absorbed, primarily metabolized in the liver via oxidation and glucuronidation.
Approximately 70% of absorbed dose is excreted in feces as unchanged drug and metabolites; about 20% is excreted renally as metabolites with less than 1% unchanged. Biliary excretion is a minor route.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
Approximately 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Not applicable; systemic levels are undetectable with topical use.
Volume of distribution is approximately 2.5-4.0 L/kg, indicating extensive tissue distribution.
Not applicable; negligible systemic absorption.
Topical: minimal systemic absorption (<0.5%). Oral: not available; vaginal: approximately 3-10% systemic absorption.
Topical: negligible systemic bioavailability (<1%) due to poor percutaneous absorption.
No dose adjustment required for topical or vaginal use. For troches, no data available; however, systemic absorption is minimal.
No dosage adjustment required for renal impairment.
No dose adjustment required for topical or vaginal use. For troches, use with caution in severe hepatic impairment due to limited data.
No dosage adjustment required for hepatic impairment.
Topical: Apply to affected area twice daily for 2-4 weeks (safe for all ages). Vaginal: Not recommended in prepubertal children. Troches: Not recommended for children under 5 years due to risk of choking; for children ≥5 years, same dose as adults (10 mg troche five times daily).
Safety and efficacy in pediatric patients below 12 years have not been established; see prescribing information for age-specific recommendations.
No specific dose adjustment required. Use same dosing as adults. Consider skin fragility with topical application.
No specific geriatric dose adjustments; use caution due to higher risk of adverse effects from prolonged use.
None
None.
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs; not for ophthalmic or oral use; use in pregnancy only if clearly needed (Category B).
Avoid contact with eyes, nose, mouth, or other mucous membranes. Discontinue if irritation or sensitization occurs. Not for oral or ophthalmic use. Use in children under 12 years not established.
Hypersensitivity to clotrimazole or any component of the formulation
Known hypersensitivity to sulconazole or any component of the formulation.
No known significant food interactions.
None known.
Clotrimazole (LOTRIMIN) topical use is not associated with increased risk of major congenital malformations. Systemic absorption is minimal (<0.5% after vaginal or topical application). First trimester vaginal use has insufficient data, but no clear teratogenic signal. Second and third trimester vaginal use is considered safe. Overall, risk is low due to negligible systemic exposure.
Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.
Minimal systemic absorption after topical or vaginal use leads to negligible excretion into breast milk. M/P ratio is not applicable due to undetectable levels. Suitable for use during breastfeeding. No adverse effects reported in nursing infants.
Not known if excreted in breast milk. Caution in nursing mothers; limited data. M/P ratio not available.
No dose adjustment required during pregnancy. Pharmacokinetics of topical/vaginal clotrimazole are unchanged due to minimal systemic absorption. Standard dosing (e.g., 100 mg vaginal tablet for 7 days or 500 mg single dose) is appropriate.
No dose adjustment required for topical use; insufficient data for systemic absorption changes.
Clotrimazole is a broad-spectrum antifungal agent; Topical formulations (cream, solution, lotion) are preferred for dermatophytosis; Vaginal tablets must be inserted high into the vagina; Avoid use on broken or inflamed skin; Monitor for local irritation.
Apply sparingly to affected area; avoid use on mucous membranes or intertriginous areas. Discontinue if irritation occurs. Not recommended for use under occlusive dressings.
Apply the medication to the affected area as directed, usually twice daily.,Wash hands before and after application unless treating hands.,For vaginal tablets, insert one tablet deep into the vagina at bedtime for 3 or 7 days.,Complete the full course even if symptoms improve.,Avoid tight-fitting clothing and synthetic fabrics; keep area clean and dry.
Use only on the skin as directed; avoid contact with eyes, mouth, or open wounds.,Wash hands before and after applying unless treating hands.,Do not cover the treated area with bandages or wrappings unless directed by a doctor.,Stop use and consult doctor if condition worsens or does not improve within 2 weeks.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOTRIMIN vs EXELDERM, answered by our medical review team.
LOTRIMIN is a Topical Antifungal that works by Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. EXELDERM is a Topical Antifungal that works by Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOTRIMIN and EXELDERM depend on the specific clinical indication. These are both Topical Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOTRIMIN is: Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.. The standard adult dose of EXELDERM is: Apply a thin layer to affected skin twice daily (morning and evening).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOTRIMIN and EXELDERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOTRIMIN is classified as Category C. Clotrimazole (LOTRIMIN) topical use is not associated with increased risk of major congenital malformations. Systemic absorption is minimal (<0.5% after vaginal or topical applicat. EXELDERM is classified as Category C. Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.